Sector: Health Care
ADAPTIVE BIOTECHNOLOGIES CORP · Meeting: June 5, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Election of Two Class I Directors
Dr. Hershberg has served since February 2013 and brings deep biotechnology executive experience; ADPT's 3-year stock return of +69.7% outperforms the peer group median by +112.9 percentage points — well above the 65-point threshold required to trigger a concern — so no TSR flag applies, and no overboarding, attendance, or independence issues were identified. Note: Dr. Hershberg is also CEO of Hillevax and chairman of Recursion Pharmaceuticals, giving him three public company board seats including ADPT, which is within the policy's four-seat limit for non-executive directors (he is a non-executive director at ADPT).
Dr. Owen has served since March 2021 and brings relevant scientific and commercialization expertise from the Gates Foundation and Merck; ADPT's 3-year stock return of +69.7% far outperforms the peer group median by +112.9 percentage points, no TSR trigger applies, and no overboarding, attendance, or independence issues were identified.
Both Class I director nominees pass all policy screens. ADPT's 3-year price return of +69.7% outperforms the compensation peer group median of -43.2% by +112.9 percentage points, which is well above the 65-point threshold for a strong positive TSR year that would be required to trigger a concern. All current directors met the 75% attendance threshold and no independence, overboarding, or familial-relationship issues were identified for the nominees.
CEO
Chad Robins
Total Comp
$9,081,690
Prior Support
98.8%%
The prior Say on Pay vote received overwhelming support of 98.8%, well above the 70% threshold that would require a response. The company's pay mix is strongly performance-oriented — 92% of CEO target compensation is at risk and tied to short- and long-term results, with at least 50% of equity in performance stock awards measured against peers over three years, satisfying the policy requirement for variable pay to dominate. ADPT's 3-year stock return of +69.7% outperforms the peer group median by +112.9 percentage points, meaning above-benchmark incentive pay is well-supported by actual shareholder experience, and no aggregate or individual pay-level red flags were identified that would override the default FOR vote.
Auditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
N/A
Non-Audit Fees
N/A
The proxy filing does not include an auditor fee table with specific dollar amounts in the text provided, so the non-audit fee ratio trigger cannot be evaluated; per policy, the tenure trigger also requires confirmed data to fire and auditor tenure is not explicitly stated in the excerpted filing text. Ernst & Young is a Big 4 firm appropriate for a $2.2B market cap company, no material restatements were disclosed, and no other negative factors were identified, so the default FOR vote applies.
Meeting held June 5, 2026
Director Elections
| Nominee | % FOR | Votes For | Withheld / Against | Result |
|---|---|---|---|---|
| Katey Owen, PhD | 97.7% | 126.8M | 3.0M | ✓ Elected |
| Robert Hershberg, PhD, MD | 71.8% | 93.2M | 36.6M | ✓ Elected |
Say on Pay
For 125.3M · Against 4.3M · Abstain 158,599
Auditor Ratification
For 142.6M · Against 484,798 · Abstain 238,779
The 2026 Adaptive Biotechnologies annual meeting presents three standard proposals — director elections, Say on Pay, and auditor ratification — all of which pass policy screens and receive a FOR determination. The company's strong 3-year stock performance, which dramatically outpaced its biotechnology peer group, robust shareholder support for executive compensation in the prior year, and a pay structure that places the vast majority of executive pay at risk in performance-linked equity all support affirmative votes across the ballot.
20 companies disclosed in 2026 proxy filing
